#AAN2018 — Investigational Pompe Therapy ATB200/AT2221 Shows Promising Results in Phase 1/2 Trial
Interim results a from Phase 1/2 clinical trial support the therapeutic benefits of investigational therapy combination ATB200/AT2221 in patients with Pompe disease. Participants in the study showed improvements in motor and respiratory function. The therapy also resulted in a durable decrease of muscle damage biomarkers. These results will be presented…